Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GTBNK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2017059289A1 ADC-115
|
|||||
| Synonyms |
Thio Hu Anti-Ly6E 9B12.v12 LC K149C-51
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Thio hu Anti-Ly6E 9B12.v12 LC K149C
|
Antibody Info | ||||
| Antigen Name |
Lymphocyte antigen 6E (LY6E)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
WO2017059289A1_ADC-115 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 24.12% (Day 13) | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | HCC1569 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1569 cells | CVCL_1255 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 50.80% (Day 13) | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | HCC1569 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1569 cells | CVCL_1255 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 66.89% (Day 13) | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (12 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | HCC1569 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1569 cells | CVCL_1255 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 79.46% (Day 13) | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (18 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | HCC1569 CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1569 cells | CVCL_1255 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.